By 49er Before some here have their say, we have seen in

New Post Public Reply Private Reply Replies (0) Message Board
CyberC
333
By 49er

Before some here have their say, we have seen in the Court Docket "UNISYS" Kay said nothing is there.

We have recently seen BravaTek Doc showing STRIKE FORCE. The Document Changed within hours of being Posted on the Board.

We've seen the Tweet from SFOR to BravaTek saying Contact me.

Kay says there is nothing there. Yeah, Right.

Imo, there is stuff there, but since not announced, these are being denied. BravaTek is so deep in the DoD and Military and NATO Arena, it's almost ridiculous.

Just my opinion
49er


WHO IS DR. THOMAS CELLUCCI ?

SOLUTIONS COMPANY NEWS INSIGHTS Contact Us
CHIEF EXECUTIVE OFFICER & CHAIRMAN


Thomas A. Cellucci PhD, MBA
Dr. Cellucci is an accomplished serial entrepreneur, seasoned senior executive and Board member possessing extensive corporate and Venture Capital experience across a number of worldwide industries.

Prior to his appointment to Bravatek’s senior management team in June 2014, Dr. Thomas Cellucci served as the US Federal Government’s first ever Chief Commercialization Officer at the US Department of Homeland Security (DHS) and the White House, working directly for President George W. Bush and President Barack Obama. There he expanded the role of public-private partnerships within government and increased opportunities for cooperative research and development activities in support across government. As Chief Commercialization Officer, Dr. Cellucci was responsible for initiatives that identified, evaluated and commercialized technology for the specific goal of rapidly developing and deploying products and services that meet the specific operational requirements of DHS’s operating components, first responders and critical infrastructure/key resources owners and operators.

Dr. Cellucci’s outreach with both the private and public sectors to establish and foster mutually-beneficial working relationships that facilitated cost-effective and efficient product, service and technology development efforts was viewed as goal for all federal agencies. He published at DHS alone, eight comprehensive books dealing with the development of operational requirements and innovative public-private partnerships in additional to over 26 articles and other resources that facilitate communication both across government and between the public and private sectors.

In 2010, while continuing to serve as Chief Commercialization Officer, Dr. Cellucci was asked to serve as Director of the Office of Public-Private Partnerships and was responsible for the effective integration of the Long Range Broad Agency Announcement (LRBAA) procurement process, Office of SAFETY Act Implementation (OSAI), Small Business Innovation Research (SBIR) Office as well as the Commercialization Office. In addition, he was asked to serve as the Director of the Research & Development Partnerships (RDP) Group to integrate and leverage the more than $9B in DHS assets and the expertise of more than 1400 team members through the group’s investments in national labs, universities, international partners, special programs and the private sector and government interagency partners to deliver solutions for the Homeland Security Enterprise (HSE). After using his integration and management skills to form a cohesive RDP group, he was then asked to serve as a Senior Counselor, as well as the Chief Commercialization Officer at DHS.

Dr. Cellucci is an accomplished serial entrepreneur, seasoned senior executive and Board member possessing extensive corporate and Venture Capital experience across a number of worldwide industries. Profitably growing high technology firms at the start-up, mid-range and large corporate level has been his trademark. In 1999, he founded a highly successful management-consulting firm, Cellucci Associates, Inc.

Dr. Cellucci authored or co-authored more than 24 books and over 192 articles on requirements development, commercialization, nanotechnology, laser physics, photonics, environmental disturbance control, MEMS test and measurement, and mistake-proofing processes. He co-authored ANSI Standard Z136.5 “The Safe Use of Lasers in Educational Institutions.” He has also held the rank of Professor or Lecturer at institutions like Princeton University, University of Pennsylvania and Camden Community College.

Dr. Cellucci was an early pioneer in advancing the field of nanotechnology in American science, engineering and manufacturing. He was instrumental in progressing America’s nanotechnology agenda through his bi-partisan work with Presidents Bill Clinton and George W. Bush and many leaders in the United States Senate. His contributions made possible the National Nanotechnology Initiative (NNI) signed by President George W. Bush in 2004 that added over $3.9 billion to the federal budget specific to the advancement of nanotechnology. Dr. Cellucci was active in discovering and fostering strategic partnerships that brought nanotechnology into a wide array of consumer products – transitioning Zyvex Corporation, as its President and Chief Operating Officer from a nanotech technology-push to market-driven enterprise.

Profitably growing firms has been his trademark. In addition, he regularly interacts with high-ranking members of the United States government—including the White House, US Senate and House of Representatives. He is often asked to serve as keynote speaker at both business and technical events around the world.

As a result of his consistent achievement in the commercialization of technologies and role as DHS’s first Chief Commercialization Officer, Dr. Cellucci has received numerous awards from industry, government and business. In addition, he has had the opportunity to interact with high-ranking members of the United States government—including the White House, US Senate and US House of Representatives—having provided several executive briefs to three Presidents of the United States and ranking Members of Congress. Dr. Cellucci is the first ever U.S. Federal Government representative to the Council on Competitiveness, a prestigious group of senior executives and thought leaders in business and academia focused on ensuring the global competitiveness of the US in technology, innovation, education and industry.

Dr. Cellucci earned a PhD in Physical Chemistry from the University of Pennsylvania (1984), an MBA from Rutgers University (1991) and a BS in Chemistry from Fordham University (1980). He has also attended and lectured at executive programs at the Harvard Business School, MIT Sloan School, Kellogg School and others.

Dr. Cellucci possesses active TS/SCI clearance.

Endonovo Therapeutics, Inc. (ENDV) Stock Research Links

ENDV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Celebrating Cultural Excellence: Fukuoka Prize 2025 Laureates Revealed

Updated Category News Views 360

Fukuoka City Announces 2025 Fukuoka Prize Winners Fukuoka City has revealed the recipients of the prestigious Fukuoka Prize for 2025, honoring remarkable individuals in the field of Asian studies and the arts. This award is presented to those who excel in preserving and enhancing the rich tapestry of Asian culture. Fukuoka City is dedicated to celebrating these...

Continue Reading
Investors Unite: Join Flywire Corporation Legal Action Today

Updated Category News Views 168

Flywire Corporation Investors Take Action Against Securities Fraud In a moment of reckoning, investors in Flywire Corporation are seizing the opportunity to join a class action lawsuit concerning alleged securities fraud. The filing of this lawsuit has been initiated to hold accountable those responsible for misleading investors during a specified period, marking a...

Continue Reading
Venus Concept Secures $2.7 Million for Growth and Innovation

Updated Category News Views 323

Venus Concept Raises Significant Funds for Future Endeavors Venus Concept Inc. (NASDAQ: VERO), a renowned name in the global medical aesthetic technology arena, recently achieved a noteworthy milestone by closing a registered direct offering that provided around $1.57 million in gross proceeds. The offering consisted of 386,700 shares of common stock, sold at $4.06 each,...

Continue Reading
Revolutionary RAGE: UPENDS Launches Game-Changing Vape System

Updated Category News Views 211

UPENDS Unveils Groundbreaking Open Pod Vape System In a remarkable stride forward for the vaping industry, UPENDS has launched their revolutionary RAGE open pod system, designed to transform how enthusiasts experience vaping. As the European market continues to evolve, this cutting-edge device positions itself as a leader in user-centric innovation and compliance. The...

Continue Reading
Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 101

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading